The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study

Andrew J Cowan; Helen Baldomero; Yoshiko Atsuta; Joseph Mikhael; Mahmoud Aljurf; Adriana Seber; Hildegard Greinix; Mickey Koh; Nina Worel; Edward N Libby; Marcelo Pasquini; Sebastian Galeano; Wael Saber; Minako Iida; Gregorio Jaimovich; Juliana Martinez Rolon; Yoshihisa Kodera; Malek Benakli; Bazuaye G Nosa; Alaa Elhaddad; Jeff Szer; Jakob Passweg; Nicolaus Kroeger; Daniel Weisdorf; Dietger Niederwieser

doi:10.1016/j.bbmt.2020.08.018

The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma

Standard

The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma : An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. / Cowan, Andrew J; Baldomero, Helen; Atsuta, Yoshiko; Mikhael, Joseph; Aljurf, Mahmoud; Seber, Adriana; Greinix, Hildegard; Koh, Mickey; Worel, Nina; Libby, Edward N; Pasquini, Marcelo; Galeano, Sebastian; Saber, Wael; Iida, Minako; Jaimovich, Gregorio; Rolon, Juliana Martinez; Kodera, Yoshihisa; Benakli, Malek; Nosa, Bazuaye G; Elhaddad, Alaa; Szer, Jeff; Passweg, Jakob; Kroeger, Nicolaus; Weisdorf, Daniel; Niederwieser, Dietger.

In: BIOL BLOOD MARROW TR, Vol. 26, No. 12, 12.2020, p. 2372-2377.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Cowan, AJ, Baldomero, H, Atsuta, Y, Mikhael, J, Aljurf, M, Seber, A, Greinix, H, Koh, M, Worel, N, Libby, EN, Pasquini, M, Galeano, S, Saber, W, Iida, M, Jaimovich, G, Rolon, JM, Kodera, Y, Benakli, M, Nosa, BG, Elhaddad, A, Szer, J, Passweg, J, Kroeger, N, Weisdorf, D & Niederwieser, D 2020, 'The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study', BIOL BLOOD MARROW TR, vol. 26, no. 12, pp. 2372-2377. https://doi.org/10.1016/j.bbmt.2020.08.018

APA

Cowan, A. J., Baldomero, H., Atsuta, Y., Mikhael, J., Aljurf, M., Seber, A., Greinix, H., Koh, M., Worel, N., Libby, E. N., Pasquini, M., Galeano, S., Saber, W., Iida, M., Jaimovich, G., Rolon, J. M., Kodera, Y., Benakli, M., Nosa, B. G., ... Niederwieser, D. (2020). The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. BIOL BLOOD MARROW TR, 26(12), 2372-2377. https://doi.org/10.1016/j.bbmt.2020.08.018

Vancouver

Cowan AJ, Baldomero H, Atsuta Y, Mikhael J, Aljurf M, Seber A et al. The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. BIOL BLOOD MARROW TR. 2020 Dec;26(12):2372-2377. https://doi.org/10.1016/j.bbmt.2020.08.018

Bibtex

@article{4c97b2a20a794445b480f65f52b27620,

title = "The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study",

abstract = "Multiple myeloma (MM) is a plasma cell neoplasm characterized by destructive bony lesions, anemia, and renal impairment. Access to effective therapy is limited globally. We report the rates and utilization of hematopoietic cell transplantation (HCT) globally from 2006-2015 to better characterize access to HCT for patients with MM. This was an analysis of a retrospective survey of Worldwide Network of Blood and Marrow Transplant sites, conducted annually between 2006-2015. Incidence estimates were from the Global Burden of Disease study. Outcome measures included total number of autologous and allogeneic HCTs by world regions, and percentage of newly diagnosed MM patients who underwent HCT, calculated by the number of transplants per region in calendar year/gross annual incidence of MM per region. From 2006 to 2015, the number of autologous HCT performed worldwide for MM increased by 107%. Utilization of autologous HCT was highest in Northern America and European regions, increasing from 13% to 24% in Northern America, and an increase from 15% to 22% in Europe. In contrast, the utilization of autologous HCT was lower in the Africa/Mediterranean region, with utilization only changing from 1.8% in 2006 to 4% in 2015. The number of first allogeneic HCT performed globally for MM declined after a peak in 2012 by -3% since 2006. Autologous HCT utilization for MM has increased worldwide in high-income regions but remains poorly utilized in Africa and the East Mediterranean. More work is needed to improve access to HCT for MM patients, especially in low to middle income countries. {\textcopyright} 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.",

author = "Cowan, {Andrew J} and Helen Baldomero and Yoshiko Atsuta and Joseph Mikhael and Mahmoud Aljurf and Adriana Seber and Hildegard Greinix and Mickey Koh and Nina Worel and Libby, {Edward N} and Marcelo Pasquini and Sebastian Galeano and Wael Saber and Minako Iida and Gregorio Jaimovich and Rolon, {Juliana Martinez} and Yoshihisa Kodera and Malek Benakli and Nosa, {Bazuaye G} and Alaa Elhaddad and Jeff Szer and Jakob Passweg and Nicolaus Kroeger and Daniel Weisdorf and Dietger Niederwieser",

year = "2020",

month = dec,

doi = "10.1016/j.bbmt.2020.08.018",

language = "English",

volume = "26",

pages = "2372--2377",

journal = "BIOL BLOOD MARROW TR",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "12",

}

RIS

TY - JOUR

T1 - The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma

T2 - An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study

AU - Cowan, Andrew J

AU - Baldomero, Helen

AU - Atsuta, Yoshiko

AU - Mikhael, Joseph

AU - Aljurf, Mahmoud

AU - Seber, Adriana

AU - Greinix, Hildegard

AU - Koh, Mickey

AU - Worel, Nina

AU - Libby, Edward N

AU - Pasquini, Marcelo

AU - Galeano, Sebastian

AU - Saber, Wael

AU - Iida, Minako

AU - Jaimovich, Gregorio

AU - Rolon, Juliana Martinez

AU - Kodera, Yoshihisa

AU - Benakli, Malek

AU - Nosa, Bazuaye G

AU - Elhaddad, Alaa

AU - Szer, Jeff

AU - Passweg, Jakob

AU - Kroeger, Nicolaus

AU - Weisdorf, Daniel

AU - Niederwieser, Dietger

PY - 2020/12

Y1 - 2020/12

N2 - Multiple myeloma (MM) is a plasma cell neoplasm characterized by destructive bony lesions, anemia, and renal impairment. Access to effective therapy is limited globally. We report the rates and utilization of hematopoietic cell transplantation (HCT) globally from 2006-2015 to better characterize access to HCT for patients with MM. This was an analysis of a retrospective survey of Worldwide Network of Blood and Marrow Transplant sites, conducted annually between 2006-2015. Incidence estimates were from the Global Burden of Disease study. Outcome measures included total number of autologous and allogeneic HCTs by world regions, and percentage of newly diagnosed MM patients who underwent HCT, calculated by the number of transplants per region in calendar year/gross annual incidence of MM per region. From 2006 to 2015, the number of autologous HCT performed worldwide for MM increased by 107%. Utilization of autologous HCT was highest in Northern America and European regions, increasing from 13% to 24% in Northern America, and an increase from 15% to 22% in Europe. In contrast, the utilization of autologous HCT was lower in the Africa/Mediterranean region, with utilization only changing from 1.8% in 2006 to 4% in 2015. The number of first allogeneic HCT performed globally for MM declined after a peak in 2012 by -3% since 2006. Autologous HCT utilization for MM has increased worldwide in high-income regions but remains poorly utilized in Africa and the East Mediterranean. More work is needed to improve access to HCT for MM patients, especially in low to middle income countries. © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.

AB - Multiple myeloma (MM) is a plasma cell neoplasm characterized by destructive bony lesions, anemia, and renal impairment. Access to effective therapy is limited globally. We report the rates and utilization of hematopoietic cell transplantation (HCT) globally from 2006-2015 to better characterize access to HCT for patients with MM. This was an analysis of a retrospective survey of Worldwide Network of Blood and Marrow Transplant sites, conducted annually between 2006-2015. Incidence estimates were from the Global Burden of Disease study. Outcome measures included total number of autologous and allogeneic HCTs by world regions, and percentage of newly diagnosed MM patients who underwent HCT, calculated by the number of transplants per region in calendar year/gross annual incidence of MM per region. From 2006 to 2015, the number of autologous HCT performed worldwide for MM increased by 107%. Utilization of autologous HCT was highest in Northern America and European regions, increasing from 13% to 24% in Northern America, and an increase from 15% to 22% in Europe. In contrast, the utilization of autologous HCT was lower in the Africa/Mediterranean region, with utilization only changing from 1.8% in 2006 to 4% in 2015. The number of first allogeneic HCT performed globally for MM declined after a peak in 2012 by -3% since 2006. Autologous HCT utilization for MM has increased worldwide in high-income regions but remains poorly utilized in Africa and the East Mediterranean. More work is needed to improve access to HCT for MM patients, especially in low to middle income countries. © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.

U2 - 10.1016/j.bbmt.2020.08.018

DO - 10.1016/j.bbmt.2020.08.018

M3 - SCORING: Journal article

C2 - 32846200

VL - 26

SP - 2372

EP - 2377

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 12

ER -